BioLineRx (BLRX) Profit After Tax Growth (3y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 33.04% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.60% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -154.28% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.53% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 26.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.93% |
| Sep 30, 2025 | 47.74% |
| Jun 30, 2025 | -19.11% |
| Mar 31, 2025 | 44.86% |
| Dec 31, 2024 | 9.53% |
| Sep 30, 2024 | -0.61% |
| Jun 30, 2024 | -58.64% |
| Mar 31, 2024 | 59.13% |
| Dec 31, 2023 | -5.02% |
| Sep 30, 2023 | -51.39% |
| Jun 30, 2023 | 39.92% |
| Mar 31, 2023 | -22.32% |
| Dec 31, 2022 | 16.57% |
| Sep 30, 2022 | -20.25% |
| Jun 30, 2022 | 10.71% |
| Mar 31, 2022 | 7.13% |
| Dec 31, 2021 | 8.68% |
| Sep 30, 2021 | 3.31% |
| Jun 30, 2021 | 12.64% |
| Mar 31, 2021 | -18.03% |
| Dec 31, 2020 | -17.67% |
| Sep 30, 2020 | 13.93% |
| Jun 30, 2020 | 11.40% |
| Mar 31, 2020 | -11.03% |
| Dec 31, 2019 | -32.06% |
| Sep 30, 2019 | 3.14% |
| Jun 30, 2019 | 51.37% |
| Mar 31, 2019 | -20.83% |
| Dec 31, 2018 | -15.67% |
| Sep 30, 2018 | -57.26% |
| Jun 30, 2018 | 44.15% |
| Mar 31, 2018 | -12.86% |
| Dec 31, 2017 | -20.61% |
| Sep 30, 2017 | -117.91% |
| Jun 30, 2017 | 47.42% |
| Mar 31, 2017 | -31.91% |
| Dec 31, 2016 | -29.31% |
| Sep 30, 2016 | -18.87% |
| Jun 30, 2016 | 0.51% |
| Mar 31, 2016 | 0.28% |